Shares of Bausch Health Companies Inc. (BHC - Free Report) were down 9.32% in response to third-quarter 2021 results.
The stock has gained 24.4% in the year so far against the industry’s decline of 5.9%.
The company’s adjusted earnings per share of $1.14 beat the Zacks Consensus Estimate of $1.07 but decreased from $1.31 reported in the year-ago quarter.
Total revenues of $2.1 billion missed the Zacks Consensus Estimate by 1.95% and fell 1% year over year. Excluding the favorable impact of foreign exchange of $19 million and the impact of divestitures and discontinuations of $46 million, revenues were flat organically year over year.
Quarter in Detail
Revenues from the Bausch + Lomb segment were $949 million, up 4% year over year. Excluding the favorable impact of $10 million from foreign exchange and the impact of divestitures and discontinuations of $4 million, revenues increased organically by 3%, primarily due to higher sales resulting from the positive impacts of recovery from the COVID-19 pandemic.
Bausch Pharma (comprising Salix, International, Ortho Dermatologics, and Diversified Products) revenues were $1.16 billion, down 5% year over year. Salix segment revenues came in at $527 million, up 6%. Xifaxan sales increased 12%.
International Rx segment revenues in the quarter were $271 million, down 12%.
Ortho Dermatologics segment revenues were $140 million in the quarter under review, down 2% year over year.
Diversified Products segment revenues were $224 million, down 19% from the year-ago quarter, primarily due to a decrease in volumes and net realized pricing.
During the third quarter, the company repaid debt by approximately $1.1 billion.
2021 Guidance Reiterated
Revenues are projected in the $8.40-$8.60 billion range.
Initial Public Offering of Solta Medical
On the last call, Bausch announced that it plans to pursue an initial public offering (IPO) of its Solta Medical business. Solta is a leading global provider in medical aesthetics with innovative and effective skin rejuvenation and body contouring solutions. The company expects to launch the proposed IPO of its Solta in December 2021 or January 2022. It also expects to launch the Bausch + Lomb IPO approximately 30 days later.
Pipeline Progress
Bausch announced statistically significant top-line results from the second phase III study evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction. The company expects to file an NDA with the FDA in the first half of 2022.
The company also completed the divestiture of Amoun Pharmaceutical Company S.A.E.
Our Take
Bausch beat on earnings in the third quarter but missed on sales. Nevertheless, management stated that many businesses continue to recover from the COVID-19 pandemic.
Zacks Rank & Stocks to Consider
Bausch currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare space are Regeneron Pharmaceuticals (REGN - Free Report) , Alkermes (ALKS - Free Report) , and Amicus Therapeutics (FOLD - Free Report) . While Regeneron and Alkermes sport a Zacks Rank #1 (Strong Buy), Amicus carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Earnings estimates for Regeneron Pharmaceuticals moved up $1.86 for 2021 in the past 30 days. The stock is up 32.3% year to date.
Earnings estimates for Alkermes moved up 7 cents for 2021 in the past 30 days. The stock is up 48.9% year to date.
Loss estimates for Amicus have narrowed by 3 cents in the past 90 days.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Shares of Bausch Health Companies Inc. (BHC - Free Report) were down 9.32% in response to third-quarter 2021 results.
The stock has gained 24.4% in the year so far against the industry’s decline of 5.9%.
The company’s adjusted earnings per share of $1.14 beat the Zacks Consensus Estimate of $1.07 but decreased from $1.31 reported in the year-ago quarter.
Total revenues of $2.1 billion missed the Zacks Consensus Estimate by 1.95% and fell 1% year over year. Excluding the favorable impact of foreign exchange of $19 million and the impact of divestitures and discontinuations of $46 million, revenues were flat organically year over year.
Quarter in Detail
Revenues from the Bausch + Lomb segment were $949 million, up 4% year over year. Excluding the favorable impact of $10 million from foreign exchange and the impact of divestitures and discontinuations of $4 million, revenues increased organically by 3%, primarily due to higher sales resulting from the positive impacts of recovery from the COVID-19 pandemic.
Bausch Pharma (comprising Salix, International, Ortho Dermatologics, and Diversified Products) revenues were $1.16 billion, down 5% year over year. Salix segment revenues came in at $527 million, up 6%. Xifaxan sales increased 12%.
International Rx segment revenues in the quarter were $271 million, down 12%.
Ortho Dermatologics segment revenues were $140 million in the quarter under review, down 2% year over year.
Diversified Products segment revenues were $224 million, down 19% from the year-ago quarter, primarily due to a decrease in volumes and net realized pricing.
During the third quarter, the company repaid debt by approximately $1.1 billion.
2021 Guidance Reiterated
Revenues are projected in the $8.40-$8.60 billion range.
Initial Public Offering of Solta Medical
On the last call, Bausch announced that it plans to pursue an initial public offering (IPO) of its Solta Medical business. Solta is a leading global provider in medical aesthetics with innovative and effective skin rejuvenation and body contouring solutions. The company expects to launch the proposed IPO of its Solta in December 2021 or January 2022. It also expects to launch the Bausch + Lomb IPO approximately 30 days later.
Pipeline Progress
Bausch announced statistically significant top-line results from the second phase III study evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction. The company expects to file an NDA with the FDA in the first half of 2022.
The company also completed the divestiture of Amoun Pharmaceutical Company S.A.E.
Our Take
Bausch beat on earnings in the third quarter but missed on sales. Nevertheless, management stated that many businesses continue to recover from the COVID-19 pandemic.
Zacks Rank & Stocks to Consider
Bausch currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare space are Regeneron Pharmaceuticals (REGN - Free Report) , Alkermes (ALKS - Free Report) , and Amicus Therapeutics (FOLD - Free Report) . While Regeneron and Alkermes sport a Zacks Rank #1 (Strong Buy), Amicus carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Earnings estimates for Regeneron Pharmaceuticals moved up $1.86 for 2021 in the past 30 days. The stock is up 32.3% year to date.
Earnings estimates for Alkermes moved up 7 cents for 2021 in the past 30 days. The stock is up 48.9% year to date.
Loss estimates for Amicus have narrowed by 3 cents in the past 90 days.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on REGN - FREE
Get the latest research report on ALKS - FREE
Get the latest research report on FOLD - FREE
Get the latest research report on BHC - FREE